Montelukast

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Montelukast sodium 5.19mg equivalent to 5 mg montelukast free acid

Disponible desde:

REX Medical Ltd

Designación común internacional (DCI):

Montelukast sodium 5.19 mg (equivalent to 5 mg montelukast free acid)

Dosis:

5 mg

formulario farmacéutico:

Chewable tablet

Composición:

Active: Montelukast sodium 5.19mg equivalent to 5 mg montelukast free acid Excipient: Aspartame Cherry flavour 11035-31 Croscarmellose sodium Hyprolose Iron oxide red Magnesium stearate Mannitol Microcrystalline cellulose

tipo de receta:

Prescription

Fabricado por:

Formosa Laboratories Inc.

indicaciones terapéuticas:

Montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm. Montelukast is indicated in adults and paediatric patients 2 years of age and older for the relief of daytime and night time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Alu foil & 3-ply alu-alu blister - 28 tablets - 24 months from date of manufacture stored at or below 25°C protect from light and moisture

Fecha de autorización:

2016-06-24